Open main menu

Psychiatrienet β

Mianserine-tranylcypromine

Revision as of 15:13, 17 November 2009 by Mariska (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from mianserine to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop mianserine
  • Before day 1: gradually reduce dosage of mianserine to a maximum of 60 mg/day.
  • Day 1: reduce a dosage of 60 mg/day to 30 mg/day.
  • Day 8: stop administration of mianserine.
Eenrichtingbord.png Start tranylcypromine
  • Day 8-21: a wash-out period of two weeks is necessary.
  • Day 22: start administration of tranylcypromine in a low dosage of 20 mg/day for one week.
  • Day 29: after this week the dosage of tranylcypromine can be increased if necessary.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.